Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach.

MLA

Kurte, Melina Sophie, et al. “Cost‐effectiveness Analysis of Transplant‐ineligible Relapsed or Refractory Diffuse Large B‐cell Lymphoma Treatment Options—Experience of the Efficiency Frontier Approach.” European Journal of Haematology, vol. 111, no. 6, Dec. 2023, pp. 895–908. EBSCOhost, https://doi.org/10.1111/ejh.14095.

APA

Kurte, M. S., Siefen, A., Jakobs, F., von Tresckow, B., Reinhardt, H. C., & Kron, F. (2023). Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach. European Journal of Haematology, 111(6), 895–908. https://doi.org/10.1111/ejh.14095

Chicago

Kurte, Melina Sophie, Ann‐Cathrine Siefen, Florian Jakobs, Bastian von Tresckow, Hans Christian Reinhardt, and Florian Kron. 2023. “Cost‐effectiveness Analysis of Transplant‐ineligible Relapsed or Refractory Diffuse Large B‐cell Lymphoma Treatment Options—Experience of the Efficiency Frontier Approach.” European Journal of Haematology 111 (6): 895–908. doi:10.1111/ejh.14095.